keyword
MENU ▼
Read by QxMD icon Read
search

ACE Alzheimer

keyword
https://www.readbyqxmd.com/read/29660936/associations-of-angiotensin-converting-enzyme-1-and-angiotensin-ii-blood-levels-and-cognitive-function
#1
Sevil Yasar, Vijay R Varma, Gregory C Harris, Michelle C Carlson
BACKGROUND: Emerging evidence suggests a possible role of the renin angiotensin system in the pathophysiologic process of Alzheimer's disease, of which angiotensin converting enzyme-1 (ACE-1) and angiotensin II (ANGII) are important proteins. Few studies evaluated associations between blood ACE-1 and none between ANGII levels, and cognition. OBJECTIVE: Our pilot study was aimed to examine associations between blood ACE-1 and ANG II levels and cognitive function in non-demented participants at baseline and over a 1-year period...
April 11, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29562541/patient-engagement-the-fundaci%C3%A3-ace-framework-for-improving-recruitment-and-retention-in-alzheimer-s-disease-research
#2
Mercè Boada, Miguel A Santos-Santos, Octavio Rodríguez-Gómez, Montserrat Alegret, Pilar Cañabate, Asunción Lafuente, Carla Abdelnour, Mar Buendía, Maria José de Dios, América Morera, Ángela Sanabria, Laura Campo, Agustín Ruiz, Lluís Tárraga
Alzheimer's disease (AD) research is at a critical time. The global society is increasingly aware of the frightening rate of growth of the human and financial burden caused by this condition and of the urgent need to halt its progression. Consequently, the scientific community holds great responsibility to quickly put in place and optimize the machinery necessary for testing new treatments or interventions. In this context demand for participants for AD research is at an all-time high. In this review, we will focus on a methodological factor that is increasingly recognized as a key factor that shapes trial populations and affects validity of results in clinical trials: patient engagement, recruitment, and retention...
2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29516284/stimulation-of-ace2-ang-1-7-mas-axis-by-diminazene-ameliorates-alzheimer-s-disease-in-the-d-galactose-ovariectomized-rat-model-role-of-pi3k-akt-pathway
#3
Ahmed S Kamel, Noha F Abdelkader, Sahar S Abd El-Rahman, Marwan Emara, Hala F Zaki, Mahmoud M Khattab
Overactivation of angiotensin-converting enzyme/angiotensin 2/angiotensin receptor-1 (ACE/Ang2/AT1) axis provokes amyloid-β-induced apoptosis and neurodegeneration in Alzheimer's disease (AD). Moreover, activation of AT1 impairs the survival pathway phosphoinositide 3-kinase/protein kinase B (PI3K/Akt). Interestingly, the coupling between ACE2/Ang(1-7)/Mas receptor (MasR) axis and PI3K/Akt activation opposes AT1-induced apoptosis. However, the effect of in vivo stimulation of MasR against AD and its correlation to PI3K/Akt is not yet elucidated...
March 7, 2018: Molecular Neurobiology
https://www.readbyqxmd.com/read/29401686/evaluation-of-polyphenol-anthocyanin-enriched-extracts-of-blackberry-black-raspberry-blueberry-cranberry-red-raspberry-and-strawberry-for-free-radical-scavenging-reactive-carbonyl-species-trapping-anti-glycation-anti-%C3%AE-amyloid-aggregation-and-microglial-neuroprotective
#4
Hang Ma, Shelby L Johnson, Weixi Liu, Nicholas A DaSilva, Susan Meschwitz, Joel A Dain, Navindra P Seeram
Glycation is associated with several neurodegenerative disorders, including Alzheimer's disease (AD), where it potentiates the aggregation and toxicity of proteins such as β-amyloid (Aβ). Published studies support the anti-glycation and neuroprotective effects of several polyphenol-rich fruits, including berries, which are rich in anthocyanins. Herein, blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts were evaluated for: (1) total phenolic and anthocyanins contents, (2) free radical (DPPH) scavenging and reactive carbonyl species (methylglyoxal; MGO) trapping, (3) anti-glycation (using BSA-fructose and BSA-MGO models), (4) anti-Aβ aggregation (using thermal- and MGO-induced fibrillation models), and, (5) murine microglia (BV-2) neuroprotective properties...
February 3, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29321566/n-domain-of-angiotensin-converting-enzyme-hydrolyzes-human-and-rat-amyloid-%C3%AE-1-16-peptides-as-arginine-specific-endopeptidase-potentially-enhancing-risk-of-alzheimer-s-disease
#5
Elena V Kugaevskaya, Alexander V Veselovsky, Maria I Indeykina, Nina I Solovyeva, Maria S Zharkova, Igor A Popov, Eugene N Nikolaev, Alexey B Mantsyzov, Alexander A Makarov, Sergey A Kozin
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder. Amyloid-β (Aβ) aggregation is likely to be the major cause of AD. In contrast to humans and other mammals, that share the same Aβ sequence, rats and mice are invulnerable to AD-like neurodegenerative pathologies, and Aβ of these rodents (ratAβ) has three amino acid substitutions in the metal-binding domain 1-16 (MBD). Angiotensin-converting enzyme (ACE) cleaves Aβ-derived peptide substrates, however, there are contradictions concerning the localization of the cleavage sites within Aβ and the roles of each of the two ACE catalytically active domains in the hydrolysis...
January 10, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29301387/pharmacogenetics-of-vascular-risk-factors-in-alzheimer-s-disease
#6
REVIEW
Ramón Cacabelos, Arun Meyyazhagan, Juan C Carril, Pablo Cacabelos, Óscar Teijido
Alzheimer's disease (AD) is a polygenic/complex disorder in which genomic, epigenomic, cerebrovascular, metabolic, and environmental factors converge to define a progressive neurodegenerative phenotype. Pharmacogenetics is a major determinant of therapeutic outcome in AD. Different categories of genes are potentially involved in the pharmacogenetic network responsible for drug efficacy and safety, including pathogenic, mechanistic, metabolic, transporter, and pleiotropic genes. However, most drugs exert pleiotropic effects that are promiscuously regulated for different gene products...
January 3, 2018: Journal of Personalized Medicine
https://www.readbyqxmd.com/read/29281341/functional-foods-and-nutraceuticals-as-dietary-intervention-in-chronic-diseases-novel-perspectives-for-health-promotion-and-disease-prevention
#7
Stephen Adeniyi Adefegha
Functional foods describe the importance of foods in promoting health and preventing diseases aside their primary role of providing the body with the required amount of essential nutrients such as proteins, carbohydrates, vitamins, fats, and oils needed for its healthy survival. This review explains the interaction of functional food bioactive compounds including polyphenols (phenolic acids [hydroxybenzoic acids and hydroxycinnamic acids], flavonoids [flavonols, flavones, flavanols, flavanones, isoflavones, proanthocyanidins], stilbenes, and lignans), terpenoids, carotenoids, alkaloids, omega-3 and polyunsaturated fatty acids, among others with critical enzymes (α- amylase, α- glucosidase, angiotensin-I converting enzyme [ACE], acetylcholinesterase [AChE], and arginase) linked to some degenerative diseases (type-2 diabetes, cardiovascular diseases [hypertension], neurodegenerative diseases [Alzheimer's disease] and erectile dysfunction)...
December 27, 2017: Journal of Dietary Supplements
https://www.readbyqxmd.com/read/29223183/conversion-between-addenbrooke-s-cognitive-examination-iii-and-mini-mental-state-examination
#8
Jordi A Matías-Guiu, Vanesa Pytel, Ana Cortés-Martínez, María Valles-Salgado, Teresa Rognoni, Teresa Moreno-Ramos, Jorge Matías-Guiu
BACKGROUND: We aim to provide a conversion between Addenbrooke's Cognitive Examination III (ACE-III) and Mini-Mental State Examination (MMSE) scores, to predict the MMSE result based on ACE-III, thus avoiding the need for both tests, and improving their comparability. METHODS: Equipercentile equating method was used to elaborate a conversion table using a group of 400 participants comprising healthy controls and Alzheimer's disease (AD) patients. Then, reliability was assessed in a group of 100 healthy controls and patients with AD, 52 with primary progressive aphasia and 22 with behavioral variant frontotemporal dementia...
December 10, 2017: International Psychogeriatrics
https://www.readbyqxmd.com/read/29213504/utility-of-the-neuropsychiatric-inventory-questionnaire-npi-q-in-the-assessment-of-a-sample-of-patients-with-alzheimer-s-disease-in-chile
#9
Gada Musa, Fernando Henríquez, Carlos Muñoz-Neira, Carolina Delgado, Patricia Lillo, Andrea Slachevsky
The Neuropsychiatric Inventory Questionnaire (NPI-Q) is an informant-based instrument that measures the presence and severity of 12 Neuropsychiatric Symptoms (NPS) in patients with dementia, as well as informant distress. Objective: To measure the psychometric properties of the NPI-Q and the prevalence of NPS in patients with Alzheimer's disease (AD) in Chile. Methods: 53 patients with AD were assessed. Subjects were divided into two different groups: mild AD (n=26) and moderate AD (n=27)...
April 2017: Dementia & Neuropsychologia
https://www.readbyqxmd.com/read/29176997/association-between-an-angiotensin-converting-enzyme-gene-polymorphism-and-alzheimer-s-disease-in-a-tunisian-population
#10
Najiba Fekih-Mrissa, Ines Bedoui, Aycha Sayeh, Hajer Derbali, Meriem Mrad, Ridha Mrissa, Brahim Nsiri
Background: The angiotensin-converting enzyme gene (ACE) insertion/deletion (I/D or indel) polymorphism has long been linked to Alzheimer's disease (AD), but the interpretation of established data remains controversial. The aim of this study was to determine whether the angiotensin-converting enzyme is associated with the risk of Alzheimer's disease in Tunisian patients. Methods: We analyzed the genotype and allele frequency distribution of the ACE I/D gene polymorphism in 60 Tunisian AD patients and 120 healthy controls...
2017: Annals of General Psychiatry
https://www.readbyqxmd.com/read/29156223/exploring-apoe-genotype-effects-on-alzheimer-s-disease-risk-and-amyloid-%C3%AE-burden-in-individuals-with-subjective-cognitive-decline-the-fundacioace-healthy-brain-initiative-facehbi-study-baseline-results
#11
Sonia Moreno-Grau, Octavio Rodríguez-Gómez, Ángela Sanabria, Alba Pérez-Cordón, Domingo Sánchez-Ruiz, Carla Abdelnour, Sergi Valero, Isabel Hernández, Maitée Rosende-Roca, Ana Mauleón, Liliana Vargas, Asunción Lafuente, Silvia Gil, Miguel Ángel Santos-Santos, Montserrat Alegret, Ana Espinosa, Gemma Ortega, Marina Guitart, Anna Gailhajanet, Itziar de Rojas, Óscar Sotolongo-Grau, Susana Ruiz, Nuria Aguilera, Judith Papasey, Elvira Martín, Esther Peleja, Francisco Lomeña, Francisco Campos, Assumpta Vivas, Marta Gómez-Chiari, Miguel Ángel Tejero, Joan Giménez, Manuel Serrano-Ríos, Adelina Orellana, Lluís Tárraga, Agustín Ruiz, Mercè Boada
INTRODUCTION: Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored. METHODS: We evaluated apolipoprotein E (APOE) ε4's effect in the risk of presenting SCD, using the Fundacio ACE Healthy Brain Initiative (FACEHBI) SCD cohort and Spanish controls, and performed a meta-analysis addressing the same question. We assessed the relationship between APOE dosage and brain amyloid burden in the FACEHBI SCD and Alzheimer's Disease Neuroimaging Initiative cohorts...
November 20, 2017: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/29081698/population-based-study-of-risk-polymorphisms-associated-with-vascular-disorders-and-dementia
#12
Óscar Teijido, Juan Carlos Carril, Ramón Cacabelos
INTRODUCTION: Cardiovascular and neurodegenerative disorders are among the major causes of mortality in the developed countries. Population studies evaluate the genetic risk, i.e. the probability of an individual carrying a specific disease-associated polymorphism. Identification of risk polymorphisms is essential for an accurate diagnosis or prognosis of a number of pathologies. AIMS: The aim of this study was to characterize the influence of risk polymorphisms associated with lipid metabolism, hypertension, thrombosis, and dementia, in a large population of Spanish individuals affected by a variety of brain and vascular disorders as well as metabolic syndrome...
October 2017: Current Genomics
https://www.readbyqxmd.com/read/29034839/pharmacogenetics-of-angiotensin-converting-enzyme-inhibitors-in-patients-with-alzheimer-s-disease-dementia
#13
Fabricio Ferreira de Oliveira, Elizabeth Suchi Chen, Marilia Cardoso Smith, Paulo Henrique Ferreira Bertolucci
BACKGROUND: While the angiotensin-converting enzyme degrades amyloid-β, angiotensinconverting enzyme inhibitors (ACEis) may slow cognitive decline by way of cholinergic effects, by increasing brain substance P and boosting the activity of neprilysin, and by modulating glucose homeostasis and augmenting the secretion of adipokines to enhance insulin sensitivity in patients with Alzheimer's disease dementia (AD). We aimed to investigate whether ACE gene polymorphisms rs1800764 and rs4291 are associated with cognitive and functional change in patients with AD, while also taking APOE haplotypes and anti-hypertensive treatment with ACEis into account for stratification...
February 22, 2018: Current Alzheimer Research
https://www.readbyqxmd.com/read/29032015/possible-positive-effect-of-the-apoe-%C3%AE%C2%B52-allele-on-cognition-in-early-to-mid-adult-life
#14
Lindsey I Sinclair, Christopher W Pleydell-Pearce, Ian N M Day
BACKGROUND: ε4 allele possession is associated with an increased risk of Alzheimer's disease. Its effects earlier in life are less well understood. Previous studies have reported both detrimental effects and a lack of effect on cognition outside dementia. We used genotype based recall from the ALSPAC study to investigate whether APOE genotype influences cognition in earlier adult life. METHODS: We invited all individuals with the rarer ε22 or ε44 genotypes and equal numbers of those with ε32, ε33 or ε34 APOE genotypes (total n invited = 1936, ages 23-67)...
December 2017: Neurobiology of Learning and Memory
https://www.readbyqxmd.com/read/28933985/acn-1-a-c-elegans-homologue-of-ace-genetically-interacts-with-the-let-7-microrna-and-other-heterochronic-genes
#15
Chanatip Metheetrairut, Yuri Ahuja, Frank J Slack
The heterochronic pathway in C. elegans controls the relative timing of cell fate decisions during post-embryonic development. It includes a network of microRNAs (miRNAs), such as let-7, and protein-coding genes, such as the stemness factors, LIN-28 and LIN-41. Here we identified the acn-1 gene, a homologue of mammalian angiotensin-converting enzyme (ACE), as a new suppressor of the stem cell developmental defects of let-7 mutants. Since acn-1 null mutants die during early larval development, we used RNAi to characterize the role of acn-1 in C...
October 2, 2017: Cell Cycle
https://www.readbyqxmd.com/read/28912299/the-test-your-memory-for-mild-cognitive-impairment-tym-mci
#16
Jeremy M Brown, Claire J Lansdall, Julie Wiggins, Kate E Dawson, Kristina Hunter, James B Rowe, Richard A Parker
BACKGROUND: To validate a short cognitive test: the Test Your Memory for Mild Cognitive Impairment (TYM-MCI) in the diagnosis of patients with amnestic mild cognitive impairment or mild Alzheimer's disease (aMCI/AD). METHODS: Two hundred and two patients with mild memory problems were recruited. All had 'passed' the Mini-Mental State Examination (MMSE). Patients completed the TYM-MCI, the Test Your Memory test (TYM), MMSE and revised Addenbrooke's Cognitive Examination (ACE-R), had a neurological examination, clinical diagnostics and multidisciplinary team review...
December 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28865943/argentinian-chilean-validation-of-the-spanish-language-version-of-addenbrooke-s-cognitive-examination-iii-for-diagnosing-dementia
#17
D Bruno, A Slachevsky, N Fiorentino, D S Rueda, G Bruno, A R Tagle, L Olavarria, P Flores, P Lillo, M Roca, T Torralva
BACKGROUND: The Addenbrooke's Cognitive Examination III (ACE-III), an adaptation of the ACE cognitive screening test, has been demonstrated to have high sensitivity and specificity in detecting cognitive impairment in patients with dementia and other neurological and psychiatric disorders. Although the Spanish-language version of the ACE-III has already been validated in Spain, it is yet to be validated in Latin America. The aim of this study was to validate the ACE-III test in an Argentinean and Chilean population...
August 30, 2017: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/28746889/molecular-recognition-between-potential-natural-inhibitors-of-the-keap1-nrf2-complex
#18
Martiniano Bello, José Antonio Morales-González
Disrupting the Keap1-Nrf2 pathway enhances Nrf2 activity, which has been identified as an important approach for the prevention of different chronic diseases in which oxidative stress and inflammation are present, such as cancer, diabetes, Alzheimer's and Parkinson's. Based on the high potential to modulate antioxidant, anti-inflammatory and anticancer properties that the discovery of Keap1-Nrf2 protein-protein interaction inhibitors would represent, the utilization of some natural compounds has emerged as a promising strategy to identify new drugs...
December 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/28713585/associations-of-centrally-acting-ace-inhibitors-with-cognitive-decline-and-survival-in-alzheimer-s-disease
#19
Karim Fazal, Gayan Perera, Mizanur Khondoker, Robert Howard, Robert Stewart
BACKGROUND: Cognitive improvement has been reported in patients receiving centrally acting angiotensin-converting enzyme inhibitors (C-ACEIs). AIMS: To compare cognitive decline and survival after diagnosis of Alzheimer's disease between people receiving C-ACEIs, non-centrally acting angiotensin-converting enzyme inhibitors (NC-ACEIs), and neither. METHOD: Routine Mini-Mental State Examination (MMSE) scores were extracted in 5260 patients receiving acetylcholinesterase inhibitors and analysed against C-/NC-ACEI exposure at the time of Alzheimer's disease diagnosis...
July 2017: BJPsych Open
https://www.readbyqxmd.com/read/28681740/cognition-in-advanced-normal-pressure-hydrocephalus-a-pilot-study-from-south-india
#20
Robert Mathew, Sauda Pavithran
BACKGROUND: Literature on cognition in normal pressure hydrocephalus (NPH) is sparse and more so on cognition in advanced NPH. OBJECTIVE: To study the cognitive profile in a hospital-based cohort of cognitively-advanced NPH. SETTINGS AND DESIGN: This was a prospective cross-sectional study. The patients included those availing dementia care service from three different tertiary care centres during a period of 5 years from 2010 to 2014. Patients were considered to have cognitively-advanced NPH if the Addenbrooke's Cognitive Examination(ACE) score was 50 or less...
July 2017: Neurology India
keyword
keyword
21424
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"